Zum Hauptinhalt springen
UB Hagen

Angiogenically effective unit dose fo FGF and method of adminstering

Whitehouse, Martha J. ; Kavanaugh, W. Michael
2006
Online Patent
Zugriff:
View record in USPTO Patent Applications (Volltext)

The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present invention is directed to a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Typically, the angiogenically effective dose comprises 0.2 μg/kg to 36 μg/kg of an FGF of any one of SEQ ID NOS:1-3, 5, 8-10, or 12-14 or an angiogenically active fragment or mutein thereof. In yet another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF of any one of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.

Titel:
Angiogenically effective unit dose fo FGF and method of adminstering
Autor/in / Beteiligte Person: Whitehouse, Martha J. ; Kavanaugh, W. Michael
Link:
Veröffentlichung: 2006
Medientyp: Patent
Sonstiges:
  • Nachgewiesen in: USPTO Patent Applications
  • Sprachen: English
  • Document Number: 20060025343
  • Publication Date: February 2, 2006
  • Appl. No: 11/238936
  • Application Filed: September 29, 2005
  • Assignees: Chiron Corporation (Emeryville, CA, US)
  • Claim: 1. A method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels in a human patient in need of treatment for coronary artery disease a therapeutically effective amount of an angiogenically active fragment or angiogenically active mutein of a recombinant fibroblast growth factor (FGF) having the sequence set forth in SEQ ID NO:3 or SEQ ID NO:5.
  • Claim: 2. The method of claim 1, wherein said therapeutically effective amount administered to said patient is a unit dose of about 0.008 mg to about 6.1 mg of said angiogenically active fragment or angiogenically active mutein of said recombinant FGF.
  • Claim: 3. The method of claim 2, wherein said therapeutically effective amount administered to said patient is a unit dose of 0.3 mg to 3.5 mg of said angiogenically active fragment or angiogenically active mutein of said recombinant FGF.
  • Claim: 4. The method of claim 1, comprising administering into one or more coronary vessels of said patient about 0.2 μg/kg to about 36 μg/kg of said angiogenically active fragment or angiogenically active mutein of said recombinant FGF.
  • Claim: 5. The method of claim 4, comprising administering into one or more coronary vessels of said patient about 0.2 μg/kg to about 2 μg/kg of said angiogenically active fragment or angiogenically active mutein of said recombinant FGF.
  • Claim: 6. The method of claim 4, comprising administering into one or more coronary vessels of said patient about 2 μg/kg to about 20 μg/kg of said angiogenically active fragment or angiogenically active mutein of said recombinant FGF.
  • Claim: 7. The method of claim 4, comprising administering into one or more coronary vessels of said patient about 20 μg/kg to about 36 μg/kg of said angiogenically active fragment or angiogenically active mutein of said recombinant FGF.
  • Claim: 8. A method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels in a human patient in need of treatment for coronary artery disease a therapeutically effective amount of a recombinant fibroblast growth factor (FGF) having the sequence set forth in SEQ ID NO:1, 2, 8-10 or 12-14 or an angiogenically active fragment or an angiogenically active mutein thereof.
  • Claim: 9. The method of claim 8, wherein said therapeutically effective amount administered to said patient is a unit dose of about 0.008 mg to about 6.1 mg of said recombinant FGF or said angiogenically active fragment or said angiogenically active mutein thereof.
  • Claim: 10. The method of claim 9, wherein said therapeutically effective amount administered to said patient is a unit dose of 0.3 mg to 3.5 mg of said recombinant FGF or said angiogenically active fragment or said angiogenically active mutein thereof.
  • Claim: 11. The method of claim 8, comprising administering into one or more coronary vessels of said patient about 0.2 μg/kg to about 36 μg/kg of said recombinant FGF or said angiogenically active fragment or said angiogenically active mutein thereof.
  • Claim: 12. The method of claim 11, comprising administering into one or more coronary vessels of said patient about 0.2 μg/kg to about 2 μg/kg of said recombinant FGF or said angiogenically active fragment or said angiogenically active mutein thereof.
  • Claim: 13. The method of claim 11, comprising administering into one or more coronary vessels of said patient about 2 μg/kg to about 20 μg/kg of said recombinant FGF or said angiogenically active fragment or said angiogenically active mutein thereof.
  • Claim: 14. The method of claim 11, comprising administering into one or more coronary vessels of said patient about 20 μg/kg to about 36 μg/kg of said recombinant FGF or said angiogenically active fragment or said angiogenically active mutein thereof.
  • Claim: 15. A method for inducing angiogenesis in the heart of a patient, comprising administering into one or more coronary vessels of a human patient in need of coronary angiogenesis a therapeutically effective amount of a recombinant fibroblast growth factor (FGF) having the sequence set forth in SEQ ID NO:1-3, 5, 8-10 or 12-14 or an angiogenically active fragment or an angiogenically active mutein thereof.
  • Claim: 16. The method of claim 15, wherein said therapeutically effective amount administered to said patient is a unit dose of about 0.008 mg to about 6.1 mg of said recombinant FGF or said angiogenically active fragment or said angiogenically active mutein thereof.
  • Claim: 17. The method of claim 15, wherein said unit dose is administered into two coronary vessels of said patient.
  • Claim: 18. The method of claim 15, further comprising the step of administering to said patient an effective amount of a glycosaminoglycan within 30 minutes of administering said recombinant FGF or said angiogenically active fragment or said angiogenically active mutein thereof.
  • Claim: 19. A unit dose of a fibroblast growth factor (FGF), comprising about 0.008 mg to about 6.1 mg of an FGF having the amino acid sequence of SEQ ID NO:1-3, 5, 8-10 or 12-14 or an angiogenically active fragment or an angiogenically active mutein thereof.
  • Claim: 20. A pharmaceutical composition comprising the unit dose of said FGF according to claim 19, and a pharmaceutically acceptable carrier, said composition being in a form and a size suitable for administration to a human patient.
  • Claim: 21. A pharmaceutical composition comprising (i) a therapeutically effective amount of a fibroblast growth factor (FGF) having the sequence of SEQ ID NO:1-3, 5, 8-10 or 12-14 or an angiogenically active fragment or an angiogenically active mutein thereof, and (ii) a pharmaceutically acceptable carrier, said composition being in a form and a size suitable for administration to a human patient, wherein said therapeutically effective amount comprises about 0.2 μ/kg to about 36 μg/kg of said FGF or said angiogenically active fragment or said angiogenically active mutein thereof.
  • Current U.S. Class: 514012/000
  • Current International Class: 61

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

oder
oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

oder
oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

xs 0 - 576
sm 576 - 768
md 768 - 992
lg 992 - 1200
xl 1200 - 1366
xxl 1366 -